Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Cepheid, Cancer Genetics Appoint New Execs

Premium

Cepheid said this week that it has appointed James Post to the position of executive vice president of North American commercial operations.

Post joins Cepheid from Alere, where he most recently served as global president of acute care. Post spent ten years at Alere and its predecessor companies Inverness Medical and Biosite. Prior to Alere, he spent approximately ten years at the United States Surgical Corporation in a variety of sales and marketing positions, including vice president of sales.


Cancer Genetics said this week that Christopher Mitton has joined the company as director of national account development and sales operations.

Mitton will lead the national expansion of CGI's Expand Dx program, designed to increase outreach and patient value for community hospitals and labs by expanding their cancer diagnostic capabilities through new testing methodologies and collaborative services. He most recently led North American sales of leukemia and solid tumor molecular diagnostic tests for Qiagen, and prior to that held diagnostic sales roles with Ipsogen, Bayer Healthcare, Abbott Diagnostics, and BioChem Immunosystems.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.